Skip to main content Skip to main content

A Much-Anticipated Eczema Drug Just Flopped in Testing

Aclaris’ bosakitug worked in the lab but never calmed skin in a midstage trial. Here’s what the miss says about how stubborn eczema can be.

Originally Published on Dermatology Times
Woman with tattooed fingers and mauve and pink nails stretching both hands out toward the camera
Unsplash/David Fanuel

For people living with atopic dermatitis, news of a new drug in testing can feel like a real reason for hope, especially when the creams and shots they’ve already tried haven’t kept flares in check. However, not every candidate makes it to the finish line. In a recent report from Dermatology Times, Aclaris Therapeutics shared that its investigational drug bosakitug fell short of both its main and secondary goals in a midstage trial for moderate-to-severe eczema.

Bosakitug is a lab-made antibody that blocks TSLP, a protein released by the skin that sits near the very start of the inflammation behind eczema’s redness and itch. The trial tracked how much each person’s eczema severity improved over 24 weeks, and the drug didn’t deliver the improvement it needed to count as a success. Aclaris hasn’t released the actual numbers or side effect rates yet, though the company did describe the drug as generally well tolerated.

What makes the result interesting is that lab tests showed the drug was doing its job on a biological level, hitting its target and quieting several immune signals linked to inflammation. Those changes just never showed up as noticeably calmer skin, which is the part that matters most to anyone trying to get through the day without scratching.

According to the report, the miss suggests that shutting down TSLP on its own may not be enough for a condition like eczema, where several inflammation pathways keep flares going at once. Aclaris already has a different approach in the works with ATI-052, a two-in-one antibody that blocks TSLP along with a second pathway that the approved eczema shot Dupixent also targets. Its next trial will be in eosinophilic esophagitis, an allergic condition of the esophagus, starting in early 2027, while the company has said at an investor conference that it plans to look for outside partners or buyers for bosakitug itself.

Because bosakitug was never approved, this result doesn’t change anything about how eczema is treated today. Dermatologists already have a growing list of treatment options for moderate-to-severe eczema, from nonsteroid creams for delicate areas like the eyelids to biologic shots and daily pills that work on itch from the inside.

Some of the approved biologics have also gotten easier to stick with, including Ebglyss, which can now be given as few as six times a year once the starting phase is done. If your eczema still isn’t under control with what you’re using now, bring it up at your next dermatology visit, since a different approach may be a better fit for your skin.

FIND A DOCTOR

Find a NewBeauty "Top Beauty Doctor" Near you

Filter doctors by location and specialty
NewBeauty Magazine Cover
NEWBEAUTY

Give the Gift of Luxury

GIVE A SUBSCRIPTION